Vivo Capital IX, LLC Sample Contracts
ROLLOVER AND SUPPORT AGREEMENTRollover and Support Agreement • October 19th, 2023 • Vivo Capital IX, LLC • Services-medical laboratories • New York
This ROLLOVER AND SUPPORT AGREEMENT (this “Agreement”) is entered into as of October 11, 2023 by and between New Genetron Holding Limited, an exempted company with limited liability incorporated under the Laws of the Cayman Islands (“Parent”) and the persons set forth on Schedule A hereto (each, a “Rollover Shareholder”, and collectively, “Rollover Shareholders”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Merger Agreement (as defined below).
Standard Contracts
JOINT FILING AGREEMENTJoint Filing Agreement • February 3rd, 2020 • Vivo Capital IX, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, no par value, of Trillium Therapeutics, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing.
Joint Filing AgreementJoint Filing Agreement • November 14th, 2024 • Vivo Capital IX, LLC • Biological products, (no disgnostic substances)
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.
JOINT FILING AGREEMENTJoint Filing Agreement • October 19th, 2023 • Vivo Capital IX, LLC • Services-medical laboratories
This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Ordinary shares, par value $0.00002 of Genetron Holdings Limited, is being filed and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • December 30th, 2019 • Vivo Capital IX, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.0001 par value, of Selecta Biosciences, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing.
